Log In
BCIQ
Print this Print this
 

HDP-101

  Manage Alerts
Collapse Summary General Information
Company Wilex AG
DescriptionAntibody-drug conjugate (ADC) composed of tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269) antibody, a specific linker and toxin amanitin
Molecular Target Tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA) (TNFRSF17) (CD269)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/19/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today